Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

Del Prato, Stefano, Kahn, Steven E, Pavo, Imre, Weerakkody, Govinda J, Yang, Zhengyu, Doupis, John, Aizenberg, Diego, Wynne, Alan G, Riesmeyer, Jeffrey S, Heine, Robert J, Wiese, Russell J, Ahmann, Andrew J, Arora, Samir, Ball, Eric M, Calderon, Rafael B, Butuk, David J, Chaychi, Leila, Chen, Michael C, Curtis, Brian M, Chochinov, Ronald, Chow, Christopher, Cone, Clancy L, Connery, Lisa, Cortes-Maisonet, Gregorio A, de Souza, Jose, Dungan, Kathleen, Bradley, David, Frias, Juan P, Gabra, Nashwa, Gaudiani, Linda, Herandez-Vazquez, Luis, Hsia, Stanley H, Jardula, Michael R, Klein, Eric J, Kutner, Mark E, Loy, Juan, Miranda, Francisco G, Nunez, Lazaro D, Mujica-Baella, Miguel, Murray, Alexander V, Oliver, Michael J, Oritz-Carrasquillo, Ramon, Palal, Betsy, Parke, Michael T, Philis-Tsimikas, Athena, Purighalla, Raman S, Rosenstock, Julio, Sathananthan, Airani, Shelton, Courtney, Sivalingam, Kanagaratnam, Sorial, Ehab, Soufer, Joseph, Stacey, Helen L, Stonesifer, Larry D, Stringam, Stanley, Van, Joanna T, Vazquez-Tanus, Jose B, Reyes, Ramon, Welch, Michelle, Karimjee, Najmuddin, Martin, Earl E, Arif, Ahmed, Jennings, Timothy W, Fraser, Neil J, Bhargava, Anuj, Wynne, Alan G, Davidson, Evelyne, Billings, Liana, Barranco-Santana, Elizabeth A, Dever, Michael E, Walsh, Patrick, Cho, Austina, Chu, James W, Shubrook, Jay, Knouse, Albert B, Nadar, Venkatesh, Lewy-Alterbaum, Lorena, Lillestol, Michael J, Humiston, Daniel J, White, Alexander J, Mayfield, Ronald K, Bitar, Fahed G, Cereto, Fernando, de la Cuesta, Carmen, De Teresa Parreno, Luis, Jodar Gimeno, Esteban, Mezquita-Raya, Pedro, Morales Portillo, Cristobal J, Quesada Charneco, Miguel, Tinahones Madueno, Francisco J, Tofe Povedano, Santiago, Vazquez, Luis, Fajardo Montañana, Carmen, Soto Gonzalez, Alfonso, Mistodie, Cristina, Szilagyi, Iosif, Filimon, Adriana, Mindrescu, Nicoleta M, Pop, Lavinia, Pascu, Marlena, Negrisanu, Gabriela D, Ciomos, Daniela, Neacsu, Valentina, Thury-Burileanu, Amalia, Liberty, Idit, Stern, Naftali, Sofer, Yael, Sack, Jessica, Shimon, Ilan, Tirosh, Amir, Ishay, Avraham, Mosenzon Ninio, Ofri, Shehadeh, Naim, Wainstein, Julio, Darawsha, Mahmud, Skripova, Dasa, Pavleova, Eva, Donicova, Viera, Kubincova, Ludmila, Sosovec, Dalibor, Merciakova, Martina, El Boreky, Fadia, St-Amour, Eric, Yared, Zeina, Blouin, Francois, Ajala, Buki, Aggarwal, Naresh K, Bajaj, Harpreet, Tailor, Chetna, Egan, Alan, O'Mahony, John, St.Onge, Natasha, Conway, James R, Akerman Augusto, Gustavo, Borges, Joao L C, Gomes Cerqueira, Maria José A, Franco, Denise R, Franco Hirakawa, Tatiana, Souza, Filipe D, Hissa, Miguel N, Pechmann, Luciana M, Calil Salim, Camila P, Russo, Luis Augusto T, Siqueira, Joselita, Sassone, Sonia A, Glenny, Jorge A, Koretzky, Martín, Aizenberg, Diego, Steinacher, Andrea, Solis, Silvana E, Nardone, Lucrecia, Perez Manghi, Federico C, Orio, Silvia I, Gelersztein, Elizabeth, Fretes, José O, Calella, Pedro R F, Zaidman, Cesar J, Chertkoff, Alejandro, Salzberg, Susana, Majul, Claudio R, Nevarez, Luis A, Violante Ortiz, Rafael M, Banda Elizondo, Ramiro G, Arjona Villicaña, Ruy D, Gonzalez Galvez, Guillermo, Calvo, Cesar G, Koscianski, Andrzej, Rudzki, Henryk, Stankiewicz, Andrzej W, Sowinski, Dariusz, Krzyzagorska, Ewa, Jozefowska, Malgorzata, Matyjaszek-Matuszek, Beata, Franek, Edward, Skokowska, Ewa, Modzelewska, Anna, Szyprowska, Ewa, Simpson, Richard W, Gilfillan, Christopher, Colquhoun, David M, Davis, Timothy M, Morbey, Claire, McCarthy, Shannon E, Kaur, Kamal, Kemp, Laurence, Shea, Antony J, Khalimov, Yuriy Sh, Miroshnichenko, Olga A, Dvoryashina, Irina V, Karpova, Irina A, Kunitsyna, Marina A, Vorokhobina, Natalia V, Galstyan, Gagik R, Bondar, Irina A., Filippov, Evgeniy V, Ershova, Olga B, Ou, Horng-Yih, Tseng, Shih-Ting, Chen, Jung-Fu, Tien, Kai-Jen, Huang, Chien-Ning, Chen, Ching-Chu, Hwu, Chii-Min, Hsia, Te-Lin, Doupis, John, Pagkalos, Emmanouil, Mouslech, Zadalla, Bargiota, Alexandra, Kotsa, Kalliopi · 2021 · The Lancet

Abstract

BACKGROUND We aimed to assess efficacy and safety, with a special focus on cardiovascular safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk inadequately controlled on oral glucose-lowering medications. METHODS This open-label, parallel-group, phase 3 study was done in 187 sites in 14 countries on five continents. Eligible participants, aged 18 years or older, had type 2 diabetes treated with any combination of metformin, sulfonylurea, or sodium-glucose co-transporter-2 inhibitor, a baseline glycated haemoglobin (HbA1c) of 7·5-10·5% (58-91 mmol/mol), body-mass index of 25 kg/m2 or greater, and established cardiovascular disease or a high risk of cardiovascular events. Participants were randomly assigned (1:1:1:3) via an interactive web-response system to subcutaneous injection of either once-per-week tirzepatide (5 mg, 10 mg, or 15 mg) or glargine (100 U/mL), titrated to reach fasting blood glucose of less than 100 mg/dL. The primary endpoint was non-inferiority (0·3% non-inferiority boundary) of tirzepatide 10 mg or 15 mg, or both, versus glargine in HbA1c change from baseline to 52 weeks. All participants were treated for at least 52 weeks, with treatment continued for a maximum of 104 weeks or until study completion to collect and adjudicate major adverse cardiovascular events (MACE). Safety measures were assessed over the full study period. This study was registered with ClinicalTrials.gov, NCT03730662. FINDINGS Patients were recruited between Nov 20, 2018, and Dec 30, 2019. 3045 participants were screened, with 2002 participants randomly assigned to tirzepatide or glargine. 1995 received at least one dose of tirzepatide 5 mg (n=329, 17%), 10 mg (n=328, 16%), or 15 mg (n=338, 17%), or glargine (n=1000, 50%), and were included in the modified intention-to-treat population. At 52 weeks, mean HbA1c changes with tirzepatide were -2·43% (SD 0·05) with 10 mg and -2·58% (0·05) with 15 mg, versus -1·44% (0·03) with glargine. The estimated treatment difference versus glargine was -0·99% (multiplicity adjusted 97·5% CI -1·13 to -0·86) for tirzepatide 10 mg and -1·14% (-1·28 to -1·00) for 15 mg, and the non-inferiority margin of 0·3% was met for both doses. Nausea (12-23%), diarrhoea (13-22%), decreased appetite (9-11%), and vomiting (5-9%) were more frequent with tirzepatide than glargine (nausea 2%, diarrhoea 4%, decreased appetite <1%, and vomiting 2%, respectively); most cases were mild to moderate and occurred during the dose-escalation phase. The percentage of participants with hypoglycaemia (glucose <54 mg/dL or severe) was lower with tirzepatide (6-9%) versus glargine (19%), particularly in participants not on sulfonylureas (tirzepatide 1-3% vs glargine 16%). Adjudicated MACE-4 events (cardiovascular death, myocardial infarction, stroke, hospitalisation for unstable angina) occurred in 109 participants and were not increased on tirzepatide compared with glargine (hazard ratio 0·74, 95% CI 0·51-1·08). 60 deaths (n=25 [3%] tirzepatide; n=35 [4%] glargine) occurred during the study. INTERPRETATION In people with type 2 diabetes and elevated cardiovascular risk, tirzepatide, compared with glargine, demonstrated greater and clinically meaningful HbA1c reduction with a lower incidence of hypoglycaemia at week 52. Tirzepatide treatment was not associated with excess cardiovascular risk. FUNDING Eli Lilly and Company.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)02188-7

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

25 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 36 references

Cited by

See all 684

Metadata

Authors
Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., Wiese, R. J., Ahmann, A. J., Arora, S., Ball, E. M., Calderon, R. B., Butuk, D. J., Chaychi, L., Chen, M. C., Curtis, B. M., Chochinov, R., Chow, C., Cone, C. L., Connery, L., Cortes-Maisonet, G. A., de Souza, J., Dungan, K., Bradley, D., Frias, J. P., Gabra, N., Gaudiani, L., Herandez-Vazquez, L., Hsia, S. H., Jardula, M. R., Klein, E. J., Kutner, M. E., Loy, J., Miranda, F. G., Nunez, L. D., Mujica-Baella, M., Murray, A. V., Oliver, M. J., Oritz-Carrasquillo, R., Palal, B., Parke, M. T., Philis-Tsimikas, A., Purighalla, R. S., Rosenstock, J., Sathananthan, A., Shelton, C., Sivalingam, K., Sorial, E., Soufer, J., Stacey, H. L., Stonesifer, L. D., Stringam, S., Van, J. T., Vazquez-Tanus, J. B., Reyes, R., Welch, M., Karimjee, N., Martin, E. E., Arif, A., Jennings, T. W., Fraser, N. J., Bhargava, A., Wynne, A. G., Davidson, E., Billings, L., Barranco-Santana, E. A., Dever, M. E., Walsh, P., Cho, A., Chu, J. W., Shubrook, J., Knouse, A. B., Nadar, V., Lewy-Alterbaum, L., Lillestol, M. J., Humiston, D. J., White, A. J., Mayfield, R. K., Bitar, F. G., Cereto, F., de la Cuesta, C., De Teresa Parreno, L., Jodar Gimeno, E., Mezquita-Raya, P., Morales Portillo, C. J., Quesada Charneco, M., Tinahones Madueno, F. J., Tofe Povedano, S., Vazquez, L., Fajardo Montañana, C., Soto Gonzalez, A., Mistodie, C., Szilagyi, I., Filimon, A., Mindrescu, N. M., Pop, L., Pascu, M., Negrisanu, G. D., Ciomos, D., Neacsu, V., Thury-Burileanu, A., Liberty, I., Stern, N., Sofer, Y., Sack, J., Shimon, I., Tirosh, A., Ishay, A., Mosenzon Ninio, O., Shehadeh, N., Wainstein, J., Darawsha, M., Skripova, D., Pavleova, E., Donicova, V., Kubincova, L., Sosovec, D., Merciakova, M., El Boreky, F., St-Amour, E., Yared, Z., Blouin, F., Ajala, B., Aggarwal, N. K., Bajaj, H., Tailor, C., Egan, A., O'Mahony, J., St.Onge, N., Conway, J. R., Akerman Augusto, G., Borges, J. L. C., Gomes Cerqueira, M. J. A., Franco, D. R., Franco Hirakawa, T., Souza, F. D., Hissa, M. N., Pechmann, L. M., Calil Salim, C. P., Russo, L. A. T., Siqueira, J., Sassone, S. A., Glenny, J. A., Koretzky, M., Aizenberg, D., Steinacher, A., Solis, S. E., Nardone, L., Perez Manghi, F. C., Orio, S. I., Gelersztein, E., Fretes, J. O., Calella, P. R. F., Zaidman, C. J., Chertkoff, A., Salzberg, S., Majul, C. R., Nevarez, L. A., Violante Ortiz, R. M., Banda Elizondo, R. G., Arjona Villicaña, R. D., Gonzalez Galvez, G., Calvo, C. G., Koscianski, A., Rudzki, H., Stankiewicz, A. W., Sowinski, D., Krzyzagorska, E., Jozefowska, M., Matyjaszek-Matuszek, B., Franek, E., Skokowska, E., Modzelewska, A., Szyprowska, E., Simpson, R. W., Gilfillan, C., Colquhoun, D. M., Davis, T. M., Morbey, C., McCarthy, S. E., Kaur, K., Kemp, L., Shea, A. J., Khalimov, Y. S., Miroshnichenko, O. A., Dvoryashina, I. V., Karpova, I. A., Kunitsyna, M. A., Vorokhobina, N. V., Galstyan, G. R., Bondar, I. A., Filippov, E. V., Ershova, O. B., Ou, H.-Y., Tseng, S.-T., Chen, J.-F., Tien, K.-J., Huang, C.-N., Chen, C.-C., Hwu, C.-M., Hsia, T.-L., Doupis, J., Pagkalos, E., Mouslech, Z., Bargiota, A., & Kotsa, K.
Affiliations
  • University of Washington (US)
  • Eli Lilly (United States) (US)
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-11
Volume
398
Issue
10313
Pages
1811-1824
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3205201678
Cited by
684
References
36
Citations by year
2026: 118 · 2025: 155 · 2024: 166 · 2023: 151 · 2022: 88 · 2021: 6
FWCI
76.89
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Funders
  • AstraZeneca
  • Sanofi
  • Eli Lilly and Company
  • Novartis Pharmaceuticals Corporation
  • Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
tirzepatide, insulin glargine, type 2 diabetes, cardiovascular risk, major adverse cardiovascular events, HbA1c, GIP/GLP-1 receptor agonist, non-inferiority, glycemic control, cardiovascular safety, metformin, SGLT2 inhibitors
MeSH terms
Insulin Glargine, Tirzepatide, Adult, Aged, Blood Glucose, Body Weight, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(21)02188-7
The paper
Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., Wiese, R. J., Ahmann, A. J., Arora, S., Ball, E. M., Calderon, R. B., Butuk, D. J., Chaychi, L., Chen, M. C., Curtis, B. M., . . . Kotsa, K. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(21)02188-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.